| 主权项 |
1. A method of assessing the teratogenic risk of a compound, said method comprising:
(1) contacting the compound with pluripotent stem cells that are being differentiated into mesendoderm; (2) measuring the protein expression of one or more mesendodermal markers selected from the group consisting of Sox17, EOMES, T-brachyury or combinations thereof; (3) determining the 1050 concentration of the compound which results in 50% inhibition of the protein expression of said one or more markers; (4) comparing the 1050 concentration determined in step (3) with the IC50 concentrations of: (a) one or more compounds with known teratogenic risks and (b) one or more compounds with known non-teratogenic risks, to establish a teratogenic risk of the compound being assessed; (5) adjusting the dose and administration of the compound to be provided to a patient based on the teratogenic risk measurement. |
